By Sabela Ojea
Spectral AI said Michael DiMaio is taking back the chairman of the board position.
The Dallas-based predictive AI company focused on medical diagnostics on Monday said that the board concluded it needed DiMaio's expertise to lead the next stage of growth of the company.
"Our focus will be on commercialization, Food and Drug Administration approval, our exceptional relationship with the Biomedical Advanced Research and Development Authority, and developing key strategic relationships," DiMaio said.
DiMaio is founded Spectral AI in 2009, served as the chief executive officer and chairman from 2011 to 2020. He is also company's second-largest shareholder.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 14, 2024 16:19 ET (20:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.